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ES6 is a novel member of the family of basic helix–
 
loop–helix mammalian homologues of 
 
Drosophila
 
Hairy
 
 
 
and Enhancer of split
 
.
 
 We have analyzed the
biochemical and functional roles of HES6 in myoblasts.
 
HES6 interacted with the corepressor transducin-like En-
hancer of split 1 in yeast and mammalian cells through its
WRPW COOH-terminal motif. HES6 repressed transcrip-
tion from an N box–containing template and also when
tethered to DNA through the GAL4 DNA binding domain.
On N box–containing promoters, HES6 cooperated with
HES1 to achieve maximal repression. An HES6–VP16 acti-
 
vation domain fusion protein activated the N box–contain-
ing reporter, conﬁrming that HES6 bound the N box in
H
 
muscle cells. The expression of HES6 was induced when
 
myoblasts fused to become differentiated myotubes.
Constitutive expression of HES6 in myoblasts inhibited
 
expression of MyoR, a repressor of myogenesis, and in-
 
duced differentiation, as evidenced by fusion into myo-
tubes and expression of the muscle marker myosin heavy
chain. Reciprocally, blocking endogenous HES6 function
by using a WRPW-deleted dominant negative HES6 mutant
led to increased expression of MyoR and completely
blocked the muscle development program. Our results
show that HES6 is an important regulator of myogenesis
and suggest that MyoR is a target for HES6-dependent tran-
scriptional repression.
 
Introduction
 
Cellular differentiation is controlled by the activation or repres-
sion of specific target genes. The basic domain helix–loop–helix
 
(bHLH)* family of transcription factors has been shown to
regulate several key developmental pathways, including neu-
rogenesis (Kageyama and Nakanishi, 1997) and myogenesis
(Molkentin and Olson, 1996; Yun and Wold, 1996). The
myogenic bHLH factors include MyoD, myogenin, Myf-5,
and MRF-4, and elegant genetic analyses have confirmed the
essential role of these factors during muscle development
(Hasty et al., 1993; Nabeshima et al., 1993; Rudnicki et al.,
1993; Rawls et al., 1998). To activate transcription, the myo-
genic bHLH factors must heterodimerize with the ubiquitous
E proteins E12, E47, or HEB (for review see Massari and
Murre, 2000). The myogenic bHLH/E protein heterodimers
then bind their cognate DNA recognition site, the E box, de-
fined by the consensus CANNTG (Massari and Murre,
2000). Several regulatory and structural muscle genes have
been shown to contain functional E boxes within their pro-
moter control regions (Weintraub et al., 1991; Schwarz et al.,
1992; Quong et al., 1993).
Myogenic bHLH factors are expressed in proliferating, un-
differentiated myoblasts, but they do not activate muscle dif-
ferentiation until myoblasts exit the cell cycle. This suggests
that inhibitors of the function of myogenic bHLH proteins
are expressed in cycling myoblasts. Several such inhibitors
have been described. The proto-oncogene c-Jun inhibits
myogenesis through direct protein–protein interactions be-
tween the proto-oncogene and MyoD (Bengal et al., 1992).
The HLH protein Id is devoid of a basic DNA binding do-
main (Benezra et al., 1990), such that it forms inactive
dimers with the ubiquitous E proteins, and prevents their
interaction with the myogenic bHLH factors. Id expression
is very rapidly downregulated within the first 24 h upon in-
duction of myogenic differentiation, and forced expression
of Id inhibits myogenesis (Jen et al., 1992).
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The activity of the myogenic bHLH factors is also directly
regulated through multiple mechanisms by other bHLH
transcription factors. Twist inhibits myogenesis by blocking
DNA binding by MyoD, by titrating E proteins, and by in-
hibiting transactivation by MEF2 (Spicer et al., 1996).
Mist1 is another bHLH factor affecting the myogenic differ-
entiation program by a combination of mechanisms. Mist1
homodimers can bind E box target sites and actively repress
transcription (Lemercier et al., 1998). In addition, Mist1
can also interact with MyoD to form inactive MyoD–
Mist1 heterodimers (Lemercier et al., 1998). Although the
Mist1 protein accumulates in myoblasts, its expression be-
comes undetectable 24 h after induction of myogenesis
(Lemercier et al., 1997) in a manner analogous to the Id ex-
pression pattern (Jen et al., 1992).
Recently, a muscle-specific bHLH protein that antago-
nizes the actions of MyoD has been cloned (Lu et al., 1999).
This protein, myogenic repressor (MyoR), is abundantly ex-
pressed in undifferentiated myoblasts in culture, but is
downregulated during differentiation. Low levels of tran-
script are detected after 3 d of differentiation regimen, but
MyoR mRNA is undetectable by 5 d after induction of the
myogenic program (Lu et al., 1999). MyoR is also specifi-
cally expressed in the developing embryo in the skeletal mus-
cle lineage between embryonic day 10.5 (E10.5) and E16.5,
and its expression is inhibited thereafter during the period of
secondary myogenesis (Lu et al., 1999). MyoR forms het-
erodimers with E proteins, but acts as a transcriptional re-
pressor after binding to regulatory E boxes (Lu et al., 1999).
Thus, MyoR appears as a lineage-restricted transcriptional
repressor of myogenesis.
Signaling through the transmembrane receptor Notch has
also been shown to prevent myogenesis in tissue culture
(Shawber et al., 1996; Nofziger et al., 1999; Wilson-Rawls et
al., 1999), as well as in 
 
Drosophila
 
 embryos (Anant et al.,
1998). Upon ligand binding, the intracellular domain of the
Notch receptor is cleaved and freed to interact with the
CBF1/KBF2/RBP-Jk transcription factors (homologues of
the 
 
Drosophila 
 
Suppressor of Hairless proteins) (Tamura et
al., 1995; Lu and Lux, 1996). The resulting complex acti-
vates the expression of candidate target genes of the HES
family (mammalian 
 
hairy
 
 and 
 
Enhancer of split
 
 homologues).
Indeed, constitutively active mutant Notch can activate the
HES1 or HES5 promoters through CBF1 binding sites (Jar-
riault et al., 1998). The HES factors form homodimers that
preferentially bind the sequence CACNAG, called an N box
(Sasai et al., 1992; Tietze et al., 1992), but show greatly re-
duced affinity towards E boxes (Sasai et al., 1992). Some
HES proteins can heterodimerize with the ubiquitous E pro-
teins, but this interaction appears to titrate the E proteins
and produce inactive dimers (Sasai et al., 1992). The DNA-
bound HES protein dimers repress transcription by recruit-
ing transducin-like Enhancer of split (TLE) proteins, the
mammalian homologues of the 
 
Drosophila 
 
Groucho gene
product, to specific DNA sites (Chen and Courey, 2000).
The interaction between HES proteins and TLE repressors is
mediated by the WRPW motif at the extreme COOH-ter-
minal of the HES family member (Chen and Courey, 2000).
Since members of the HES family are transcriptional re-
pressors, the net effect of activating Notch is to repress gene
transcription (Artavanis-Tsakonas et al., 1995). Although
the functional linkage between Notch and HES family
members has been demonstrated in the regulation of neu-
ronal differentiation using genetic manipulations (Ohtsuka
et al., 1999), this link remains hypothetical in the case of
muscle differentiation. HES1 has been reported to inhibit
the activity of MyoD (Sasai et al., 1992), and this has been
proposed as a mechanism whereby Notch inhibits myogene-
sis. However, more recent data have shown that Notch sig-
naling inhibits myogenesis through an HES1-independent
pathway (Shawber et al., 1996; Rusconi and Corbin, 1998;
Nofziger et al., 1999; Wilson-Rawls et al., 1999). Moreover,
activated forms of Notch do not upregulate the expression of
HES1 in muscle cells (Shawber et al., 1996). Thus, the role
of HES proteins in myoblasts remains to be determined.
Recently, a novel HES family member, HES6, was identi-
fied (Bae et al., 2000; Koyano-Nakagawa et al., 2000; Pissara
et al., 2000; Vasiliauskas and Stern, 2000). HES6 is charac-
terized by a shorter loop region within its helix–loop–helix
domain, which prevents it from binding the N box (Bae et
al., 2000; Koyano-Nakagawa et al., 2000). HES6 was shown
to antagonize HES1 and prevent it from repressing transcrip-
tion (Bae et al., 2000). By doing so, HES6 acted to promote
retinal cell differentiation in explant cultures and 
 
Xenopus
 
embryos (Bae et al., 2000; Koyano-Nakagawa et al., 2000).
In contrast to HES1, HES6 is expressed by both undifferen-
tiated and differentiated cells. During mouse embryogenesis,
HES6 expression can be measured from E8.5 onwards, and
high levels of HES6 transcripts were detected in tissues
where Notch affects cell fate decisions, such as the nervous
system, muscle, and thymus (Bae et al., 2000; Koyano-Naka-
gawa et al., 2000; Pissara et al., 2000; Vasiliauskas and Stern,
2000). During the muscle development program, HES6 was
shown to be expressed during both myoblast commitment
and differentiation, and is thus the only HES gene expressed
throughout myogenesis in the embryo (Pissara et al., 2000;
Vasiliauskas and Stern, 2000).
We examined the role of HES6 in myoblastic gene tran-
scription and in the regulation of myoblast differentiation in
culture. We report that HES6 binds TLE1 through its
COOH-terminal WRPW tetrapeptide to repress transcrip-
tion from N box–containing promoters in undifferentiated
muscle cells. Interestingly, HES6 did not antagonize HES1
in myoblasts but cooperated in an additive manner to fur-
ther repress transcription. Endogenous HES6 expression is
induced during myogenesis in culture, and perturbing this
pattern of expression affected the differentiation of the cells.
When HES6 expression was enforced in myoblasts, MyoR
expression was downregulated, and differentiation occurred
even in the presence of high serum concentration. On the
other hand, interfering with endogenous HES6 function by
expressing a WRPW-deleted dominant negative HES6 mu-
tant induced MyoR and inhibited myogenesis. Thus, al-
though HES6 was seen to promote myoblast differentiation
as it was reported to promote neurogenesis (Bae et al., 2000;
Koyano-Nakagawa et al., 2000), the mechanisms involved
appear quite different and point to cell-specific actions of
HES6 in muscle cells. Our results implicate HES6 as a key
regulator of the muscle development program and suggest
that MyoR is a downstream target of HES6. 
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Results
 
We serendipitously cloned a partial murine HES–related
cDNA in a yeast two-hybrid screen using a bait derived from
a tetratricopeptide repeat (TPR) (Lamb et al., 1995) do-
main–containing protein. The functional relevance of the
HES protein–TPR domain interaction remains unclear and
has not been explored further. Database searches identified
expressed sequence tags that allowed cloning of a nearly full-
length cDNA. While this work was in progress, the first
characterization of a novel HES family member, HES6, was
published (Bae et al., 2000; Koyano-Nakagawa et al., 2000;
Pissara et al., 2000; Vasiliauskas and Stern, 2000). Sequence
comparison revealed that the clone that we isolated is identi-
cal to the published mouse HES6 cDNA but lacks the first
16 amino acids. As described previously, HES6 contains the
hallmark features of HES family members, including the
Orange domain, a proline-rich region, the conserved proline
residue within the basic region, the helix–loop–helix struc-
ture, and the COOH-terminal WRPW motif (Bae et al.,
2000). A distinctive feature of HES6 is the shorter loop re-
gion, which lacks four or five residues when compared with
other family members (Bae et al., 2000). The shorter loop
prevents HES6 from binding the canonical HES DNA
binding site, the N box (CACNAG) (Bae et al., 2000; Koy-
ano-Nakagawa et al., 2000).
The WRPW motif at the extreme COOH-terminal of
HES family members mediates interaction between HES
proteins and TLE repressors, the mammalian homologues of
the 
 
Drosophila
 
 Groucho gene product (Chen and Courey,
2000). We tested whether HES6 interacts with TLE1 using
the yeast two-hybrid protein interaction assay. Western blot
assays of extracts from yeast cells transfected with pAD-HES6
(GAL4 activation domain fused to HES6) or pAD-HES6-
 
 
 
(a deletion engineered to remove the WRPW COOH-termi-
nal peptide from the HES6 sequence) confirmed that both
fusion proteins are produced in yeast cells (Fig. 1 a; proteins
migrating at 
 
 
 
32 kD). Yeast cells that were cotransfected
with pBD-TLE1 (GAL4 DNA binding domain fused to
TLE1) and pAD-HES6 grew on selection plates lacking Leu,
Trp, and His to the same extent as cells transfected with the
control plasmids, pBD-p53 and pAD-T (Fig. 1 d). The abil-
ity of the transformed cells to grow on His
 
 
 
 medium indi-
cates that a transcriptionally competent GAL4 complex was
reconstituted due to the interaction between TLE1 and
 
Figure 1.
 
HES6 interacts with TLE1 in yeast cells.
 
 Yeast two-
hybrid protein interaction assay. (a) Immunoblots of extracts from 
yeast cells transfected with pAD–HES6 (w.t.) or pAD–HES6-
 
 
 
 (
 
 
 
) 
confirmed that both fusion proteins are produced in yeast cells. Left 
lane, molecular size markers in kiloDaltons. (b) Bait and target 
plasmids used to cotransfect yeast. BD, binding domain of GAL4; 
AD, activation domain of GAL4. The positive controls, pBD-p53 
and pAD-T, were supplied with Stratagene’s HybriZAP kit. (c) 
Growth on Leu
 
 
 
, Trp
 
 
 
 plates. (d) Growth on Leu
 
 
 
, Trp
 
 
 
, and His
 
 
 
 
plates. The ability of the transformed cells to grow on His
 
 
 
 medium 
indicates that a transcriptionally competent GAL4 complex was 
reconstituted due to the interaction between TLE1 and HES6. Note 
that the interaction requires the WRPW motif, as the HES6-
 
 
 
 
deletion mutant, deprived of this motif, did not interact with TLE1 
to support growth on His
 
 
 
 plates. 
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HES6. The interaction was confirmed in a positive filter as-
say for 
 
 
 
-galactosidase activity (unpublished results). In con-
trast, cells cotransfected with pBD-TLE1 and pAD-HES6-
 
 
 
,
while growing on Leu
 
 
 
, Trp
 
 
 
 media (Fig. 1 c), could not
grow on His
 
 
 
 plates (Fig. 1 d) and did not express 
 
 
 
-gal (un-
published results). These results show that HES6 interacted
with TLE1 in yeast cells through the WRPW motif.
To establish the physiological relevance of this interaction,
we coprecipitated HES6 and TLE1 from transfected mam-
malian cells. C2C12 myoblasts were cotransfected with
pGST-TLE1, a mammalian expression vector encoding a
glutathione 
 
S
 
-transferase (GST)–TLE1 fusion protein, and
mammalian expression vectors for 6xHis epitope–tagged
 
HES6 or HES6-
 
 
 
. Cell extracts were precipitated using glu-
tathione-Sepharose beads and probed with anti-GST or
anti-6xHis antibodies. Cells cotransfected with the empty
pGST vector and HES6 served as controls for the specific-
ity of the coprecipitation. Immunoblotting of transfected
cell extracts confirmed that the epitope-tagged HES6 and
HES6-
 
 
 
 proteins were expressed at equivalent levels in
transfected cells (unpublished results). GST and GST–
TLE1 were expressed at similar levels and efficiently pulled
down by the glutathione-Sepharose beads (Fig. 2 a, lanes
1–4). Probing the precipitates with the anti-6xHis antibody
revealed that the epitope-tagged HES6 was specifically co-
precipitated with GST–TLE1 (lane 8) and that the GST–
TLE1–HES6 interaction required the WRPW sequence,
since HES6-
 
 
 
 was not coprecipitated with GST–TLE1
(lane 7). The binding of HES6 to GST–TLE1 involved the
TLE1 moiety of the fusion protein, since expressing GST
alone did not coprecipitate HES6 (lane 5).
We used a mammalian two-hybrid assay to confirm the
coprecipitation results. Human 293 cells were transiently
transfected with a reporter construct containing the lucifer-
ase gene under the control of the SV-40 promoter linked
to five tandem GAL4 upstream activation sequence sites
(5xGAL4UAS). This modified SV-40 promoter is basally ac-
tive in mammalian cells (Grbavec et al., 1998). Cotransfection
with a plasmid encoding the DNA binding domain of GAL4
(GAL4bd) resulted in a roughly 2.5-fold activation of tran-
scription above basal level, as reported previously (Grbavec et
al., 1999) (Fig. 2 b, compare lanes 1 and 2). In contrast,
expression of a fusion protein of GAL4bd and HES6
(GAL4bd–HES6) had no transactivating effect; rather it re-
sulted in a complete repression of GAL4bd-mediated activa-
tion and an 
 
 
 
50% repression of basal transcription (Fig. 2 b,
lane 4). This result shows that HES6 mediates transcriptional
repression when targeted to DNA (see also Fig. 4 below). Im-
portantly, a fusion protein of GAL4bd and a truncated form
of HES6 lacking the COOH-terminal WRPW (GAL4bd–
HES6-
 
 
 
) motif was not able to repress basal transcription
(Fig. 2 b, lane 6). GAL4bd–HES6 and GAL4bd–HES6-
 
 
 
were expressed at equal levels (unpublished results). These re-
sults suggest that the WRPW motif of HES6 is involved in its
transcription repression ability by recruiting TLE corepres-
sors. To test this possibility, cells were cotransfected with a
plasmid encoding a fusion protein of TLE1 and the potent ac-
tivation domain of the herpes simplex virion protein VP16.
This manipulation was shown to convert TLE1 from a repres-
sor to an activator (Wang et al., 2000). The expression of
TLE1–VP16 had no significant effect on reporter gene ex-
pression in the presence of GAL4bd alone (Fig. 2 b, lane 3).
In contrast, TLE1–VP16 blocked the ability of GAL4bd–
HES6 to repress basal transcription and partly reduced acti-
vated transcription (Fig. 2 b, lane 5). This shows that TLE1–
VP16 was recruited to the promoter site by interaction with
HES6. This interaction required the WRPW motif of HES6
because TLE1–VP16 had no significant effect on GAL4bd–
HES6-
 
 
 
 (Fig. 2 b, lane 7). Together, these findings show that
HES6 interacts with TLE proteins via its WRPW domain in
mammalian cells and that this interaction is important for the
ability of HES6 to mediate transcriptional repression.
The shorter loop region of the HES6 protein prevents it
from binding N box–containing DNA (unpublished results)
Figure 2. HES6 binds TLE1 in mammalian cells. (a) C2C12 
myoblasts were cotransfected with expression vectors for GST 
epitope–tagged TLE1 and 6xHis epitope–tagged HES6. Cell extracts 
were precipitated with glutathione-Sepharose beads and analyzed 
by Western blotting using anti-GST (lanes 1–4) or anti-6xHis (lanes 
5–8) antibodies. HES6, but not HES6- , was coprecipitated with 
GST–TLE1. The empty GST expression vector (lanes 1 and 5) and 
empty HES6 expression vector, pEBVHis (lanes 2 and 6), served 
as negative controls for the specificity of the interaction. (b) Mam-
malian two-hybrid assay. 293 cells were cotransfected with the 
p5xGAL4UAS-SV40-luc reporter and pcDNA3-GAL4bd, pcDNA
3-GAL4bd–HES6, pcDNA3-GAL4bd–HES6- , or pTLE1–VP16, 
alone or in combination, as indicated below the graph. Cells were 
collected 24 h after transfection and luciferase activity was assayed. 
Results are expressed as a percentage of expression relative to cells 
transfected with the reporter and empty vector alone. Means   SD 
of three experiments are shown. 
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(Bae et al., 2000; Koyano-Nakagawa et al., 2000). However,
HES6 was shown to antagonize the HES1-mediated repres-
sion of N box–containing promoters (Bae et al., 2000). We
attempted to determine the influence of the WRPW se-
quence, and thus the binding of TLE factors, on N box–
dependent transcriptional repression using expression vec-
tors for HES6, HES6-
 
 
 
, and HES1. These experiments were
performed in C2C12 myoblasts, which express TLE pro-
teins (Grbavec et al., 1998). The HES6 and HES6-
 
 
 
 pro-
teins were expressed at similar levels and localized to the nu-
cleus in transfected cells (Fig. 3). Surprisingly, in transiently
transfected C2C12 myoblasts, HES6 suppressed transcrip-
tion from reporter templates containing N boxes (Fig. 4 a).
This effect was specific for the N box and required the
WRPW COOH-terminal peptide, as HES6-
 
 
 
 did not affect
transcription from the N box–containing promoter (Fig. 4
a). The level of inhibition achieved by transfecting HES6 in
myoblasts was similar to the inhibition observed when
HES6 was tethered to DNA through the GAL4 DNA bind-
ing domain (Fig. 2 b, lane 4) and also to the level of inhibi-
tion generated by the transfection of similar amounts of
HES1 in C2C12 cells (compare Fig. 4, a and c). We inter-
pret these results to mean that in muscle cells, HES6 can
dimerize with a bHLH partner to bind the N box, recruit
TLE proteins, and repress transcription. To test this hypoth-
esis, we engineered an HES6–VP16 fusion protein by join-
ing the potent activation domain of the herpes simplex vir-
Figure 3. HES6 and HES6-  localize to the nucleus in muscle 
cells. C2C12 myoblasts were transiently transfected with epitope-
tagged HES6 and HES6-  expression vectors and stained for 
immunofluorescence detection using antibodies directed against 
the epitope tag. Bar, 10  m.
Figure 4. HES6 binds the N box to repress transcription and does 
not antagonize HES1 in myoblasts. Transient transfection of C2C12 
myoblasts with HES6, HES6- , HES6-VP16, and HES1 expression 
vectors, alone or in combination. (a) Transcriptional repression by 
HES6 in C2C12 cells. The control template (pActinLUC) did not 
contain N boxes, whereas the test template (p6NactinLUC) contained 
six copies of a canonical N box sequence. Results are expressed as a 
percentage of expression relative to cells transfected with the reporter 
and empty vector alone. (b) The HES6–VP16 activation domain 
fusion protein binds N boxes and activates the N box–containing 
reporter. Joining the VP16 activation domain to HES6 transformed 
HES6 from a repressor into an activator, and HES6–VP16 activated 
transcription specifically from the N box–containing promoter, 
whereas the full-length VP16 protein had no effect. Results are 
expressed as fold induction relative to cells transfected with the 
reporter alone. Vector, empty expression vector backbone. (c) HES6 
cooperates with HES1 to maximally repress N box–dependent tran-
scription in muscle cells. The reporter construct was p6NactinLUC. 
Results are expressed as a percentage of expression relative to cells 
transfected with the reporter and empty vector alone. 
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ion protein VP16 (amino acids 416–490) in frame to the
COOH end of HES6-
 
 
 
. This manipulation transformed
HES6 from a repressor into an activator, and HES6–VP16
activated transcription specifically from the N box–contain-
ing promoter, whereas the full-length VP16 protein had no
effect (Fig. 4 b). These results confirm that HES6 binds to
N boxes in myoblasts.
As reported previously in other cell types (Sasai et al.,
1992; Bae et al., 2000), HES1 repressed transcription from
the N box–containing reporter template in muscle cells (Fig.
4 c). When cotransfected with HES1 in myoblasts, HES6
did not antagonize HES1-mediated repression, but led to
additive inhibition (Fig. 4 c). This suggests that HES6-con-
taining heterodimers can cooperate with HES1 dimers to
further inhibit transcription from N box–containing pro-
moters in an additive manner.
The distinct repressor activity of HES6 in undifferenti-
ated myoblasts (Fig. 4), as compared with its HES1 antago-
nist activity in other cell types (Bae et al., 2000), prompted
us to examine the expression pattern of HES6 during myo-
blast differentiation and to investigate a putative role for
HES6 in myogenesis. Fig. 5 shows that expression of the
HES6 mRNA was induced when confluent cultures of
C2C12 myoblasts were switched to low serum differentia-
tion medium (DM). Expression was maximal after 7 d in
DM (lane 3), when differentiated, fused myotubes became
apparent in the cultures (unpublished results). Low levels of
HES6 transcripts were detected in committed, undifferenti-
ated myoblasts (lane 1). We used gain-of-function and dom-
inant negative strategies to determine the role of HES6 in
myogenic differentiation. Pools of stably transfected C2C12
cells expressing HES6 or HES6-
 
 
 
 were isolated and cul-
tured in high serum growth media (GM) or placed in DM,
and their morphology and the expression of the muscle dif-
ferentiation marker, myosin heavy chain (MHC), were ex-
amined. Cells transfected with the empty expression vector
behaved as the parental cells and served as controls. Two in-
dependent pools of HES6- and HES6-
 
 
 
–expressing cells
were isolated and exhibited similar characteristics, but only
one set of results is presented here. The expression of the
epitope-tagged transgenes, HES6 and HES6-
 
 
 
, was moni-
tored by Western blot assay using the anti-6xHis antibody.
The stable pools expressed comparable levels of HES6 and
HES6-
 
 
 
 (unpublished results).
When placed in DM, control and HES6-expressing cells
differentiated to form fused myotubes (Fig. 6, a and b), and
MHC protein expression was readily detected after 3 and 5
d in low serum (Fig. 7 a, lanes 2, 3, 5, and 6). In contrast,
HES6-
 
 
 
–expressing cells never fused in DM (Fig. 6 c) and
the undifferentiated myoblasts did not express MHC (Fig. 7
a, lanes 7–9). These observations suggest that HES6-
 
 
 
 acted
Figure 5. Induction of HES6 mRNA expression during differentiation 
of C2C12 myoblasts. The cells were grown to confluence in growth 
medium then switched to low serum DM. RNA was extracted after 
0, 3, and 7 d of differentiation and analyzed by Northern blot assay 
using the HES6 cDNA. The membrane was then stripped and 
reprobed with the GAPDH cDNA to monitor for loading variations. 
Note the induction of HES6 expression during the differentiation of 
the C2C12 myoblasts into fused myotubes.
Figure 6. HES6 can modulate the 
myogenic differentiation program. 
Stable pools of C2C12 myoblasts 
expressing HES6 (b, e, and h), HES6-  (c, 
f, and i), or the empty expression 
vector (a, d, and g) were induced to 
differentiate in DM (a, b, c) or maintained 
in GM for 4 (d–f) or 7 (g–i) d postcon-
fluency. Note the absence of fused 
myotubes in HES6- –expressing cells, 
even after 5 d in DM (c). At 4 d post-
confluency in GM (d–f), HES6-expressing 
cells begin to differentiate (e). Differenti-
ation of HES6-expressing cells in GM is 
more evident at 7 d, where several 
myotubes stain positively for MHC (h). 
Control (d and g) and HES6- –express-
ing cells (f and i) never differentiate and 
don’t stain for MHC (g and i) in GM. 
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as a dominant negative mutant to block endogenous HES6
function and prevent myogenesis. We also examined the be-
havior of cultures maintained in GM at confluency. Control
and HES6-
 
 
 
–expressing cells retained their single-cell myo-
blast morphology when maintained in GM for 4 d postcon-
fluency (Fig. 6, d and f), whereas some HES6-expressing
cells began to fuse into myotubes under the same conditions
(Fig. 6 e). MHC expression remained undetectable in all
cultures during this period (Fig. 7 b). After 7 d in GM at
confluency, HES6-expressing cells differentiated into myo-
tubes (Fig. 6 h) expressing MHC (Figs. 6 h and 7 c, lane 1).
Control cells (Fig. 6 g) and cells expressing HES6-
 
 
 
 (Fig. 6
i) did not differentiate under the same conditions and did
not turn on the expression of MHC (Fig. 6, g and i, respec-
tively, and Fig. 7 c, lane 2). Together, the data from the
dominant negative mutant expression and gain-of-function
expression demonstrate that HES6 is a key regulator of the
myogenic differentiation program.
Since HES6 acted as a transcriptional repressor in myo-
blasts, the induction of HES6 during C2C12 differentiation
suggests that HES6 must repress the expression of an inhibi-
tor of myogenesis in order for the muscle differentiation
 
program to proceed. The kinetics of the induction of HES6
closely parallel the time-course of the downregulation of
MyoR, which has recently been identified as such a repressor
of myogenesis (Lu et al., 1999). The reciprocal expression
patterns of HES6 and MyoR suggest that MyoR could be an
HES6 target. We tested whether constitutive expression of
HES6 or its dominant negative mutant HES6-
 
 
 
 could
modulate the expression pattern of MyoR in confluent cul-
tures of C2C12 myoblasts. MyoR expression and the expres-
sion of the ubiquitous GAPDH gene were assessed using re-
verse transcriptase (RT)-PCR under linear amplification
conditions, allowing accurate comparison of expression lev-
els. MyoR expression was readily detectable in control cells
(Fig. 8, lane 1). Constitutive expression of HES6 inhibited
MyoR expression (lane 2), whereas blocking endogenous
HES6 function with the HES6-
 
 
 
 mutant dramatically aug-
mented MyoR mRNA levels (lane 3). These data provide
strong circumstantial evidence that HES6 could regulate
MyoR expression.
 
Discussion
 
We have shown that HES6 binds TLE family members to
repress transcription from an N box–containing promoter in
muscle cells, and that it can cooperate with HES1 to achieve
maximal transcriptional repression in these cells. These ob-
servations contrast with previous findings showing that
HES6 antagonized HES1 repressor activity in fibroblasts
and retinal explant cultures (Bae et al., 2000). The apparent
muscle-specific repressor activity of HES6 prompted us to
study the role of HES6 in myogenesis. Undifferentiated myo-
blasts express minimal levels of HES6 mRNA, and HES6
expression is induced in differentiated myotubes. Gain-of-
Figure 7. Expression of MHC in HES6 and HES6-  stable transfor-
mants. Whole cell extracts were prepared from the cultures described 
in the legend to Fig. 6 and assayed for MHC expression using 
Western blotting. (a) Control (ctrl) cells expressing the empty 
pEBVHis vector, HES6, and HES6-  transfected cells were placed 
in low serum DM for the indicated period of time. Note that 
HES6- –expressing cells do not differentiate and do not express 
MHC. (b) The cells were maintained in GM for 4 d postconfluency. 
(c) The cells were kept in GM for 7 d after they reached confluence. 
Note that HES6-expressing cells differentiated and expressed MHC 
even when maintained in GM. In each panel, equal loading of 
sample wells was assessed by costaining with an anti-TATA binding 
protein (TBP) antibody.
Figure 8. MyoR is a putative downstream target of HES6. MyoR 
expression was monitored by RT-PCR in confluent cultures of 
C2C12 cells expressing HES6, HES6- , or transfected with the 
empty expression vector (CTRL). Under the conditions used, 
amplification was within the linear range of the reaction and 
GAPDH-specific primers yielded equivalent amounts of amplimers. 
Note the reduced expression of MyoR in HES6-expressing cells, and 
the dramatically increased expression in HES6- –transfected cells. 
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function and dominant negative mutations in cultured myo-
blasts revealed that HES6 is an important regulator of the
muscle development program.
 
HES6 and transcription
 
Tethering HES6 to DNA by fusing it to the GAL4 DNA
binding domain leads to transcriptional repression of
GAL4 upstream activation sequence-containing reporter
templates (Fig. 2 b). The repression required the WRPW
tetrapeptide at the COOH terminus of HES6 and involved
recruitment of the TLE1 corepressor. Can HES6 bind the
canonical HES binding site, the N box, to repress tran-
scription? Recent work has shown that the length of the
loop region of bHLH molecules is critical for DNA bind-
ing activity and has identified a loop residue critical for
DNA binding (Winston and Gottesfeld, 2000). Since the
HES6 loop is 4 to 5 residues shorter than related family
members, it was postulated and demonstrated that HES6
dimers could not bind to an N box sequence (Bae et al.,
2000; Koyano-Nakagawa et al., 2000). We have confirmed
these results in electrophoretic mobility shift assays (un-
published results). However, HES1–HES6 heterodimers
were shown to bind DNA (Bae et al., 2000), demonstrat-
ing that HES6 can heterodimerize with other bHLH mole-
cules to bind the N box. In fibroblasts and developing
mouse retina, HES6 suppressed HES1 from repressing
transcription (Bae et al., 2000). The proposed mechanism
was that the structure of the HES1–HES6 heterodimer
does not allow interaction with TLE corepressors, or that
HES6 sequestered TLE molecules from HES1 (Bae et al.,
2000). The interaction of HES6 with TLE molecules was
not examined in that study. We have shown that HES6 can
bind TLE corepressors in yeast and mammalian cells, and
that this binding requires the WRPW COOH-terminal
tetrapeptide.
In myoblasts, HES6 did not antagonize HES1, and coex-
pression of HES1 and HES6 led to additive repressor activity
(Fig. 4). This could be due to a specific effect of the HES1–
HES6 heterodimer in muscle cells, that could result from tis-
sue-specific posttranslational modifications of one or both of
the dimer partners. Alternatively, HES6 could dimerize with
a muscle-specific bHLH partner to bind the N box, recruit
TLE corepressors, and inhibit transcription. In this fashion,
the HES6-containing heterodimers could cooperate with
HES1 homodimers to fully repress N box–dependent tran-
scription. We favor this interpretation since (a) we have ob-
served that HES6 can repress transcription from N box–con-
taining templates when transfected alone in myoblasts; (b)
the HES6–VP16 activation domain fusion protein bound to
N boxes to activate the N box–containing reporter (Fig. 4).
What molecule dimerizes with HES6 in muscle cells? We
were not able to detect interaction between HES6 and E pro-
teins in EMSAs or pull-down assays (unpublished results),
suggesting that ubiquitous bHLH proteins are not the part-
ners involved in the repressor function of HES6 in myo-
blasts. Other HES family members appear mostly expressed
in neural tissue (Lobe, 1997), although HES5 expression was
detected in developing somites (Barrantes et al., 1999), sug-
gesting that HES5 could dimerize with HES6 to repress
transcription during muscle development. Recently, a new
subclass of bHLH proteins, HRT1–3, was characterized and
shown to be expressed in the developing heart and in the der-
momyotome and sclerotome (Nakagawa et al., 1999). Thus,
these Hairy-related transcriptional regulators represent puta-
tive dimerization partners for HES6 in developing muscle. It
will prove interesting to determine whether a posttransla-
tionally modified HES1–HES6 dimer or a distinct HES6-
containing heterodimer mediate HES6-dependent repres-
sion in differentiating muscle cells.
 
HES6 and myogenesis
 
Forcing constitutive HES6 expression in myoblasts induced
myotube fusion and expression of the muscle differentiation
marker MHC (Figs. 6 and 7), even in cultures maintained in
high serum concentration, where fusion is normally in-
hibited. Reciprocally, blocking the activity of endogenous
HES6 by expressing a dominant negative mutant form of
HES6 that lacks the corepressor-recruiting WRPW tet-
rapeptide inhibited differentiation when confluent cultures
were placed in low serum media. These results show that
HES6 plays an essential role during myoblast differentiation
in culture. Is HES6 regulating myogenesis in vivo? A recent
study describing the pattern of expression of HES6 in mouse
embryos shows that HES6 is expressed during both myo-
blast commitment and differentiation, supporting a role for
HES6 in the regulation of the muscle development program
(Pissara et al., 2000; Vasiliauskas and Stern, 2000). We have
also detected HES6 expression in adult muscle using North-
ern blot hybridization (unpublished results). The engineer-
ing of tissue-specific HES6 mouse mutants will help to for-
mally prove the role of HES6 during muscle development.
Myogenic bHLH factors are expressed in proliferating,
undifferentiated myoblasts, but they do not activate muscle
differentiation until myoblasts exit the cell cycle. This sug-
gests that inhibitors of the function of myogenic bHLH pro-
teins are expressed in cycling myoblasts. Several such inhibi-
tors have been identified, including c-Jun (Bengal et al.,
1992), Id (Jen et al., 1992), Twist (Spicer et al., 1996),
Mist-1 (Lemercier et al., 1998), and MyoR (Lu et al., 1999).
Since HES6 acts as a transcriptional repressor in myoblasts,
the induction of HES6 during C2C12 differentiation sug-
gests that HES6 must repress the expression of an inhibitor
of myogenesis in order for myotube differentiation to pro-
ceed. Amongst the various inhibitors of myogenesis listed
above, MyoR appears like the best candidate target for
HES6-mediated repression. Indeed, the kinetics of the
downregulation of Id and Mist1 expression during myotube
differentiation do not match the time-course of HES6 in-
duction (Jen et al., 1992; Lemercier et al., 1998), whereas
Twist is not expressed in growing myoblasts (Hebrok et al.,
1994). Finally, these genes are strongly expressed in tissues
showing high levels of HES6 transcripts postnatally (unpub-
lished results), arguing against an inhibitory role of HES6 in
the control of their expression. On the contrary, the kinetics
of the induction of HES6 closely parallel the time-course of
MyoR downregulation, suggesting that MyoR could be a
downstream target of HES6. Indeed, modulating HES6 ex-
pression in myoblasts via gain-of-function or dominant neg-
ative mutations affected MyoR expression, strongly support-
ing a role for HES6 in the transcriptional control of MyoR 
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expression. The analysis of the MyoR promoter region could
identify N boxes or other response elements through which
HES6-containing dimers could regulate MyoR transcription
in muscle cells.
To properly regulate cell fate choice and ensure normal
organogenesis, several signaling pathways have been shown
to inhibit skeletal myoblast differentiation by interfering
with the expression or activity of myogenic bHLH proteins.
Signaling through Notch inhibits myogenesis through an
HES-1–independent pathway in tissue culture (Shawber et
al., 1996; Rusconi and Corbin, 1998; Nofziger et al., 1999;
Wilson-Rawls et al., 1999). Preliminary results using North-
ern blot analysis of RNA extracted from parental C2C12
cells and from C2C12 myoblasts transfected with constitu-
tively active forms of Notch (Nofziger et al., 1999) show
that activated Notch inhibited the induction of HES6 in
myoblasts cultured in differentiation medium (G. Weinmas-
ter and R. St-Arnaud, personal communication). Similarly,
coculture of C2C12 cells with L cells expressing the Notch
ligand Jagged1 (Lindsell et al., 1995) revealed that ligand ac-
tivation of Notch inhibited HES6 induction (G. Weinmas-
ter and R. St-Arnaud, personal communication). Although
it will be important to confirm that this inhibition is not due
to a general block in the myogenic program induced by
Notch signaling, these results suggest that HES6 could rep-
resent a key target in Notch signaling during myogenesis.
Although the proposed mechanisms are significantly dif-
ferent, our results do support a role for HES6 in promoting
instead of inhibiting differentiation, as was reported for neu-
rogenesis (Bae et al., 2000; Koyano-Nakagawa et al., 2000).
It will prove interesting to identify the partners, targets, and/
or posttranslational modifications involved in the muscle-
specific functions of HES6.
 
Materials and methods
 
Cloning of the HES6 cDNA and expression vectors
 
A partial mouse HES6 cDNA was isolated serendipitously in a yeast two-
hybrid screen (see Results). Sequence comparison analysis identified over-
lapping expressed sequence tags that allowed cloning of a nearly full-
length cDNA using PCR. The HES6 cDNA, lacking the first 16 amino
acids, was then subcloned into a yeast two-hybrid assay vector (pGAD-
GH; CLONTECH Laboratories, Inc.) or mammalian expression vectors
(pEBVHis and pcDNA4/TO/myc-His; Invitrogen) using conventional meth-
odology. The HES6-
 
 
 
 mutant (lacking the COOH-terminal WRPW tet-
rapeptide) was engineered by PCR using the wild-type cDNA as template
and subcloned into the same expression vectors. Plasmids pcDNA3–
GAL4bd–HES6 and pcDNA3–GAL4bd–HES6-
 
 
 
 were obtained by sub-
cloning the appropriate PCR products into the filled-in BamHI site of
pcDNA3–GAL4bd. The HES6–VP16 activation domain fusion protein was
engineered by subcloning the PCR-amplified VP16 domain (amino acids
416–490) in frame downstream from HES6-
 
 
 
 in the pcDNA4/TO/myc-His
vector. Construct pTLE1–VP16 has been described previously (Wang et al.,
2000) and was provided by Dr. D.K. Granner (Vanderbilt University
School of Medicine, Nashville, TN)
 
Yeast two-hybrid protein interaction assay
 
Yeast cells were cotransfected with pGBT9–TLE1 (pBD–TLE1) (Grbavec
and Stifani, 1996) and pGAD–GH–HES6 (pAD–HES6) or pGAD–GH–
HES6-
 
 
 
 (pAD–HES6-
 
 
 
) following a protocol derived from the HybriZAP
two-hybrid instruction manual (Stratagene). Positive interaction was scored
based on growth on media lacking tryptophan, leucine, and histidine, sup-
plemented with 20 mM 3-aminotriazole, and by testing for expression of
the lacZ reporter gene as recommended (Stratagene). Western blot assays
to confirm expression of the fusion proteins in yeast were performed using
standard protocols (Ausubel et al., 1993).
 
Coprecipitation assay
C2C12 myoblasts (Blau et al., 1985) were grown to 50–60% confluency in
100-mm tissue culture dishes and transfected using the GenePORTER
transfection reagent (Gene Therapy Systems) according to the manufac-
turer’s protocol. Cells were cotransfected with 3.0  g of either pEBVHis–
HES6, pEBVHis–HES6- , or the empty pEBVHis vector (Invitrogen), together
with 3.0  g of pEBG–GST–TLE1 (McLarren et al., 2000) or pEBG–GST (Mi-
zushima and Nagata, 1990). Cells were collected 24 h posttransfection, re-
suspended in homogenization buffer (25 mM Tris-HCl, pH 7.8, 200 mM
NaCl, 0.5% Triton X-100), homogenized, and centrifuged (2 min at 6000
rpm). The cell extract supernatant was recovered and incubated with glu-
tathione-Sepharose beads overnight at 4 C with gentle agitation. The beads
were then collected by centrifugation, washed four times in homogeniza-
tion buffer, and finally resuspended in SDS-PAGE buffer.
Immunoblotting
After electrophoresis, proteins were transferred to nitrocellulose mem-
branes and probed by Western blotting using standard protocols (Ausubel
et al., 1993). Detection was performed using the ECL Western blotting
detection system (Amersham Pharmacia Biotech). Primary antibodies in-
cluded anti-GST (1:3,000 dilution; Amersham Pharmacia Biotech), anti-
6xHis (1:2,500 dilution; CedarLane Laboratories), anti-TBP (1:1,000 dilu-
tion; Upstate Biotechnology), and the MF20 anti-MHC hybridoma (1:500
dilution) (Bader et al., 1982). HRP-conjugated secondary antibodies (Santa
Cruz Biotechnology, Inc.) were used at a 1:20,000 dilution.
Transient transfection assays
Human 293 cells were transiently transfected using the SuperFect reagent
(QIAGEN) according to the manufacturer’s instructions. Transfections in-
cluded 1.0  g of the luciferase reporter plasmid p5xGAL4UAS–SV-40-luc
(Grbavec et al., 1998) and 1.0  g each of pcDNA3–GAL4bd, pcDNA3–
GAL4bd–HES6, pcDNA3–GAL4bd–HES6- , or pTLE1–VP16 (Wang et al.,
2000) alone or in combination. Total amount of DNA was normalized at 3.0
 g by addition of the empty pcDNA3 vector (Invitrogen) and included 0.25
 g of pCMV– -galactosidase plasmid DNA to provide a means of normaliz-
ing the assays for transfection efficiency. Cells were collected 24 h after
transfection. C2C12 myoblasts were grown in 6-well plates and transfected
using 15  l of GenePORTER reagent, 0.3  g of reporter construct
(p6NactinLUC or pActinLUC) (Sasai et al., 1992), 0.3–1.6  g of pRc/CMV-
HES1 (Grbavec and Stifani, 1996), pEBVHis-HES6, or pEBVHis-HES6- ,
alone or in combination, and 50 pg of the internal control reporter, pcmvRL
(Promega). The total amount of DNA transfected was standardized to 3.0  g
by addition of empty pEBVHis vector. Cells were harvested 48 h posttrans-
fection and luciferase activity was assayed using the Dual Luciferase assay
kit (Promega) in a Monolight 2010 (Analytical Luminescence Laboratory).
The data from multiple experiments were pooled and the mean   SEM were
calculated. The final results are expressed as a percentage of expression rela-
tive to cells transfected with the reporter and empty vector alone. Transfec-
tions with the HES6–VP16 fusion protein were performed using 8.0  l of Fu-
GENE 6 reagent as per the manufacturer’s recommended procedure (Roche
Diagnostics). Total DNA was standardized to 2.0  g and comprised 0.5 ng
of pcmvRL internal control reporter (Promega), 0.2  g of reporter construct
(p6NactinLUC or pActinLUC) (Sasai et al., 1992), and 1.5  g of empty vec-
tor (pcDNA4/TO/myc-His), HES6-VP16, or pMSVP16, a mammalian expres-
sion vector for the full length VP16 protein (Triezenberg et al., 1988). At the
time of transfection, cells were switched to medium containing 2% horse se-
rum and harvested 24 h later. Luciferase activity was measured as described
above and results are expressed as mean fold induction   SEM of three ex-
periments performed in duplicates.
Immunocytochemistry
C2C12 cells were plated at 1.2   10
5 cells per 35-mm plate on gelatin-
coated cover slips and transfected as described above with pcDNA4–HES6
or pcDNA4–HES6- . The cells were rinsed in PBS, fixed in 4% parafor-
maldehyde, and permeabilized with 0.2% Triton X-100. After blocking
with 1% BSA and 10% normal goat serum, the cells were incubated with
an anti-myc epitope antibody (Santa Cruz Biotechnology, Inc.; 1:200 dilu-
tion), rinsed, then treated with the secondary rhodamine-conjugated anti–
mouse IgG antibody (Jackson ImmunoResearch Laboratories) at 1:200 in
PBS containing 1% BSA. After washes, the coverslips were mounted in
Vectashield (Vector Laboratories) and the cells visualized on a Leica mi-
croscope at 200 .
RNA expression analysis
Total RNA was isolated using the RNeasy miniprep kit (QIAGEN). Probes
used were a mouse GAPDH cDNA fragment (Piechaczyk et al., 1984) for1170 The Journal of Cell Biology | Volume 154, Number 6, 2001
assessing loading and a 1.2-kb HES6 fragment (bHLH domain to 3 -UTR).
Northern hybridization was performed as per Amersham Pharmacia Bio-
tech’s Rapid-hyb instruction manual. For RT-PCR, first-strand cDNA syn-
thesis was performed with SuperScript II reverse transcriptase (Canadian
Life Technologies) followed by PCR amplification with 2  l of the RT reac-
tion, 0.1  Ci of 
32P-dCTP, and MyoR- or GAPDH-specific primers (se-
quences available on request). After a 2 min denaturation at 99 C, PCR
conditions were set as follows: 94 C for 1 min, 60 C for 30 s, and 72 C for
1 min, for 23 cycles. Amplimers were separated on 6% polyacrylamide
gels and exposed to film. Control reactions using 21 or 25 cycles (unpub-
lished results) confirmed that amplification of both the GAPDH and MyoR
fragments was within the linear range of the reaction, allowing semiquanti-
tative comparison of expression levels from the RT-PCR data.
Myogenic conversion assay
C2C12 myoblasts were transfected as described above with 1  g of
pEBVHis, pEBVHis–HES6, or pEBVHis–HES6- . Stable transfectants were
isolated by pooling hygromycin-resistant cell colonies. Cells were main-
tained in GM (DME supplemented with 10% fetal bovine serum) until they
reached confluency, then switched to DM (DME with 2% horse serum) to
induce myotube fusion. In one experiment, confluent cultures were main-
tained in GM for up to 7 d. MHC expression was detected by Western
blotting as described above or by direct staining of fixed cells. In brief,
cells were rinsed in PBS, fixed in 3% paraformaldehyde in PBS for 40 min
at room temperature, then blocked with 5% goat serum in PBS for 1 h. The
blocking solution was removed, and the fixed cells were incubated for 1 h
with the MF20 antibody (Bader et al., 1982) at 1:500 dilution in PBS. After
rinsing the primary antibody, the HRP-conjugated secondary antibody
(1:10,000) was added for 1 h. Excess antibody was washed away with PBS,
and immunoreactive cells were stained with the VectaStain Elite ABC kit
(Vector Laboratories) for 30 min.
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